What does the MTHFR gene do?

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme responsible for converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF, or methylfolate). Methylfolate is the primary circulating form of folate and serves as the methyl donor for converting homocysteine back to methionine through the methionine synthase reaction. This conversion is the entry point for the methylation cycle - the biochemical process that produces S-adenosylmethionine (SAMe), the universal methyl donor required for DNA methylation, neurotransmitter synthesis, phospholipid production, and detoxification reactions. When MTHFR is impaired, the entire methylation cycle slows, homocysteine accumulates, SAMe production falls, and the downstream consequences affect virtually every physiological system that depends on methylation.

What are the C677T and A1298C variants?

C677T (rs1801133) and A1298C (rs1801131) are the two most clinically significant MTHFR polymorphisms. C677T involves a cytosine-to-thymine substitution at position 677 that converts alanine to valine in the enzyme protein, producing a thermolabile enzyme with reduced activity - approximately 35% reduction in heterozygotes (CT genotype) and 70% reduction in homozygotes (TT genotype). A1298C involves a cytosine-to-adenine substitution at position 1298 that converts glutamate to alanine, reducing enzyme activity less severely - approximately 10-20% reduction in heterozygotes. Compound heterozygosity (carrying one C677T variant and one A1298C variant) reduces enzyme activity comparably to C677T homozygosity.

What symptoms are associated with MTHFR variants?

MTHFR variants do not cause a single defined syndrome but rather reduce the efficiency of methylation-dependent processes throughout the body, contributing to multiple overlapping patterns: elevated homocysteine with increased cardiovascular risk; impaired neurotransmitter synthesis contributing to anxiety, depression, ADHD, and mood instability; increased neural tube defect risk in pregnancy; impaired detoxification capacity; fatigue from reduced SAMe availability; and potentially increased risk of certain cancers related to impaired DNA methylation fidelity. Not all carriers experience symptoms - dietary folate intake, cofactor status, and coexisting genetic variants in related pathways significantly modulate clinical expression.

Why can't people with MTHFR variants just take folic acid?

Standard folic acid (the synthetic oxidized form of folate in most supplements and fortified foods) must be converted through multiple enzymatic steps - including the MTHFR reaction - before it can be used for methylation. In individuals with reduced MTHFR activity, this conversion is impaired, meaning folic acid supplementation does not reliably raise methylfolate levels. High-dose folic acid in MTHFR carriers may actually worsen outcomes by accumulating as unmetabolized folic acid (UMFA) in circulation, which competes with methylfolate for folate receptors and may paradoxically worsen methylation efficiency. The appropriate intervention is 5-methyltetrahydrofolate (5-MTHF or methylfolate) - the active, pre-converted form that bypasses the MTHFR enzyme entirely.

How is MTHFR variant status treated?

The primary intervention is replacing standard folic acid with activated methylfolate (5-MTHF) at doses appropriate to the severity of the variant and the patient's clinical presentation. Methylcobalamin (active B12) is supplemented alongside methylfolate because B12 is required by methionine synthase, the enzyme that uses methylfolate to recycle homocysteine. Riboflavin (B2) supports MTHFR enzyme function and is particularly important in C677T homozygotes. Pyridoxal-5-phosphate (active B6) supports the transsulfuration pathway that provides an alternative homocysteine clearance route. Dietary adjustments emphasizing naturally occurring folate from leafy greens and legumes, while reducing folic acid-fortified processed foods, reduce UMFA accumulation. Homocysteine monitoring provides the most clinically useful functional readout of treatment effectiveness.

Home / Lab Reference Library / MTHFR Gene Genetic Markers

MTHFR Gene

MTHFR encodes methylenetetrahydrofolate reductase, the rate-limiting enzyme in the folate cycle that converts dietary folate into methylfolate - the form required to produce SAMe, recycle homocysteine, methylate DNA, and synthesize neurotransmitters. Variants in MTHFR are among the most common clinically significant genetic polymorphisms, affecting approximately 40-60% of the population and influencing cardiovascular risk, mental health, pregnancy outcomes, detoxification capacity, and lifelong methylation efficiency.

Genetic Markers Methylation Cardiovascular Risk

40-60% of the general population carries at least one MTHFR variant - making this one of the most common genetic polymorphisms in clinical medicine

70% Drop in MTHFR enzyme activity with C677T homozygous variant - reducing conversion of folate to active methylfolate by more than two-thirds

Addressable MTHFR variants are among the most clinically actionable genetic findings - dietary and supplementation strategies effectively bypass the enzyme deficiency

Schedule a Consultation

← Back to Lab Reference Library

Biomarker: MTHFR Gene (C677T / A1298C) | Category: Genetic Markers | Test type: SNP genotyping | Specimen: Saliva or blood (DNA)

1. What Is MTHFR?

MTHFR stands for methylenetetrahydrofolate reductase - the enzyme encoded by the MTHFR gene on chromosome 1p36.3. It catalyzes the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF), commonly called methylfolate. This is the rate-limiting step in the folate cycle and the gateway reaction that makes folate usable for methylation chemistry throughout the body.

Methylfolate has one primary downstream function of enormous metabolic consequence: it donates its methyl group to homocysteine via the enzyme methionine synthase (with vitamin B12 as a cofactor), converting homocysteine to methionine. Methionine is then converted to S-adenosylmethionine (SAMe), the universal methyl donor that powers more than 200 methylation-dependent reactions - including DNA methylation, histone modification, neurotransmitter synthesis (dopamine, serotonin, epinephrine), phospholipid production for cell membranes, myelin synthesis, creatine production, and hepatic detoxification reactions.

When MTHFR is functioning at reduced capacity due to genetic variants, the entire downstream cascade slows. Methylfolate production falls, homocysteine accumulates rather than being recycled, SAMe production decreases, and the methylation-dependent processes throughout the body run at reduced efficiency. The clinical consequences range from subclinical - mild elevation of homocysteine and modest reduction in methylation capacity - to clinically significant depending on variant severity, dietary folate intake, B12 status, and coexisting genetic variants in related pathways.

2. The Two Primary Variants: C677T and A1298C

Variant	rs Number	Enzyme Activity	Homocysteine Effect
C677T Heterozygous (CT)	rs1801133	Approx 65% of normal	Mildly elevated; variable by nutritional status
C677T Homozygous (TT)	rs1801133	Approx 30% of normal	Significantly elevated; most clinically impactful MTHFR genotype
A1298C Heterozygous (AC)	rs1801131	Approx 80-90% of normal	Minimally elevated; primarily affects neurotransmitter synthesis pathway
A1298C Homozygous (CC)	rs1801131	Approx 60% of normal	Moderately elevated; clinically significant
Compound Heterozygous (CT + AC)	Both loci	Approx 30-40% of normal	Comparable to C677T homozygous; full clinical management warranted

Population frequency: C677T heterozygosity occurs in approximately 40% of the general population; C677T homozygosity in approximately 10-15%. A1298C heterozygosity occurs in approximately 30-40%. Compound heterozygosity (one C677T + one A1298C) occurs in approximately 15-20%. These are among the most common genetic variants in clinical medicine, which is why MTHFR testing has become a standard component of comprehensive functional medicine workups.

3. The Methylation Cycle - Why MTHFR Matters So Broadly

Understanding why MTHFR has such wide-ranging clinical consequences requires understanding methylation. Methylation is the transfer of a methyl group (CH3) from one molecule to another - a chemical transaction that modifies the target molecule's function. SAMe, produced from methionine (which requires methylfolate for its recycling from homocysteine), is the methyl donor for the majority of the body's methylation reactions. When MTHFR reduces methylfolate production, SAMe availability falls, and the following methylation-dependent processes are affected:

Methylation-Dependent Processes Affected

DNA methylation - epigenetic gene regulation; impaired DNA methylation affects cancer suppressor gene expression
Neurotransmitter synthesis - SAMe methylates norepinephrine to epinephrine, and supports serotonin and dopamine metabolism
Myelin basic protein synthesis - impaired methylation affects myelin sheath integrity and neurological function
Phosphatidylcholine production for cell membranes and bile - liver function and lipid metabolism
Creatine synthesis - 40% of SAMe consumption goes to creatine production; impaired methylation reduces creatine availability
Detoxification phase II reactions - hepatic sulfation and glucuronidation depend on adequate SAMe
Histamine inactivation - SAMe methylates histamine to N-methylhistamine for clearance

Clinical Consequences of Reduced Methylation

Elevated homocysteine - direct cardiovascular risk factor causing endothelial damage and thrombotic tendency
Anxiety, depression, mood instability - from impaired neurotransmitter methylation and catecholamine metabolism
Fatigue and cognitive fog - from reduced SAMe availability for brain function
Increased neural tube defect risk in pregnancy - critical first-trimester requirement for methylfolate
Impaired detoxification - reduced capacity to clear heavy metals, environmental toxins, and medications
Histamine intolerance - impaired histamine clearance from reduced SAMe-dependent methylation
Elevated cancer risk - from impaired DNA methylation of tumor suppressor regions

4. Conditions with Established MTHFR Associations

Cardiovascular disease: elevated homocysteine from MTHFR variants causes endothelial injury, promotes thrombosis, and is an independent risk factor for coronary artery disease, stroke, and peripheral vascular disease - the homocysteine-cardiovascular connection is one of the strongest established links from MTHFR research
Depression and anxiety: SAMe is required for the synthesis and metabolism of serotonin, dopamine, and norepinephrine; reduced methylation from MTHFR impairs neurotransmitter production and catabolism, and many patients with treatment-resistant depression carry C677T homozygous or compound heterozygous variants
Neural tube defects: MTHFR C677T homozygosity is the strongest established genetic risk factor for neural tube defects - this is why all women of reproductive age are advised to take folate, and why methylfolate rather than folic acid is preferred in MTHFR carriers planning pregnancy
Recurrent pregnancy loss: impaired methylation and elevated homocysteine increase thrombotic risk in placental vasculature, contributing to recurrent miscarriage in some MTHFR carriers
Autism spectrum disorder: MTHFR variants are overrepresented in ASD populations; impaired methylation affects brain development, and methylfolate supplementation is studied as a therapeutic approach in some ASD individuals
Histamine intolerance: SAMe methylates histamine for clearance; MTHFR-impaired methylation reduces histamine metabolism capacity and can amplify histamine intolerance symptoms
Chronic fatigue and fibromyalgia: methylation impairment from MTHFR variants is a common finding in these populations and contributes to mitochondrial dysfunction, neurotransmitter imbalance, and impaired energy metabolism
Medication sensitivities: impaired detoxification from reduced methylation capacity can alter pharmacokinetics of medications dependent on methylation for inactivation or clearance

5. Why Folic Acid Is Problematic for MTHFR Carriers

This is one of the most clinically important practical points in MTHFR management. Standard folic acid - the synthetic oxidized form used in most vitamin supplements and mandated in fortified grain products - must be converted through a series of enzymatic steps before it can enter the methylation cycle as methylfolate. The final and rate-limiting step in this conversion is the MTHFR reaction. In patients with impaired MTHFR activity, this conversion is blocked at exactly the step where it matters most.

High-dose folic acid supplementation in MTHFR carriers does not resolve the problem - it compounds it. Unconverted folic acid accumulates as unmetabolized folic acid (UMFA) in circulation. UMFA competes with methylfolate for the same folate receptor binding sites in the brain and elsewhere, potentially blocking the entry of whatever methylfolate is produced despite the MTHFR impairment. Multiple studies associate high UMFA levels with impaired natural killer cell function, reduced cognitive performance, and paradoxically worse methylation efficiency. The solution is bypassing the MTHFR enzyme entirely by supplementing with 5-methyltetrahydrofolate (5-MTHF) directly.

6. Treatment Approach for MTHFR Variants

Intervention	Rationale	Key Considerations
5-MTHF (methylfolate) supplementation	Bypasses MTHFR enzyme; provides active folate directly for homocysteine recycling and SAMe production	Start low and titrate up; some patients - particularly those with anxiety - are sensitive to high-dose methylfolate and experience overmethylation symptoms requiring dose reduction
Methylcobalamin (active B12)	Required cofactor for methionine synthase, the enzyme that uses methylfolate to convert homocysteine to methionine	Preferred over cyanocobalamin, which requires conversion steps that may be impaired in some patients; sublingual delivery improves absorption independent of intrinsic factor
Pyridoxal-5-phosphate (active B6)	Supports the transsulfuration pathway - an alternative homocysteine clearance route that converts it to cysteine and then glutathione	Particularly important in patients with elevated homocysteine who are slow responders to methylfolate and B12 alone
Riboflavin (B2)	MTHFR enzyme requires FAD (derived from riboflavin) as a cofactor; riboflavin supplementation may partially restore enzyme activity, particularly in C677T homozygotes	400mg/day of riboflavin has been shown to lower homocysteine specifically in C677T TT carriers, adding to the methylfolate and B12 protocol
Dietary folate optimization	Naturally occurring folate in leafy greens and legumes is in polyglutamate forms that still require MTHFR processing but are less problematic than synthetic folic acid	Reduce folic acid-fortified processed foods; increase dark leafy greens, lentils, asparagus, and avocado
Homocysteine monitoring	The most reliable functional readout of methylation cycle efficiency and treatment response	Target homocysteine below 7 micromol/L in functional medicine context; recheck 8-12 weeks after initiating supplementation protocol

7. Monitoring Treatment - What to Track

MTHFR genotype is fixed - it does not change. But its functional consequences are highly modifiable through nutrition, supplementation, and lifestyle, and monitoring confirms that the intervention is achieving the desired effect. Homocysteine is the most direct functional marker of methylation cycle efficiency. A reduction in homocysteine toward the functional target below 7 micromol/L following methylfolate and B12 protocol initiation confirms adequate methylation cycle support. Plasma methylmalonic acid (MMA) confirms functional B12 status independent of serum B12. RBC folate reflects tissue folate stores more accurately than serum folate and should rise with appropriate methylfolate supplementation.

8. Related Labs and Tests

HomocysteineInflammation & Cardiovascular

→

Folate (RBC)Nutrients & Micronutrients

→

Vitamin B12Nutrients & Micronutrients

→

Methylmalonic AcidNutrients & Micronutrients

→

VDR GeneGenetic Markers

→

9. Frequently Asked Questions

I have MTHFR C677T heterozygous. Should I be concerned?

Heterozygous C677T reduces MTHFR enzyme activity by approximately 35%, which is meaningful but not as impactful as homozygosity. Many CT heterozygotes have normal homocysteine and no detectable clinical consequences when their diet is adequate in naturally occurring folate and B12. The most useful next step is measuring your homocysteine level. If it is below 7-8 micromol/L and you feel well, active supplementation may not be required. If homocysteine is elevated or you have symptoms consistent with methylation impairment - fatigue, mood instability, treatment-resistant depression, histamine intolerance - a targeted methylfolate and B12 protocol is appropriate.

Can MTHFR variants be detected through consumer genetic tests like 23andMe?

Yes - 23andMe and similar consumer genomic services do genotype both C677T and A1298C as part of their standard panel. The raw data can be downloaded and analyzed through third-party interpretation tools. However, consumer genetic reports often do not include MTHFR in their health reports due to regulatory considerations, and the raw data interpretation requires some genomics literacy. Clinical MTHFR testing ordered through a functional medicine provider includes interpretation and clinical recommendations alongside the genotype results.

What is the right dose of methylfolate for MTHFR carriers?

There is no universal dose. Starting low - typically 400 to 800 mcg of 5-MTHF - and titrating based on homocysteine response and symptom tolerance is the recommended approach. Some patients, particularly those with anxiety or other sensitivity patterns, experience overmethylation symptoms including irritability, racing thoughts, or worsening anxiety at higher doses - which typically resolve by reducing the dose or temporarily using niacin (which consumes SAMe) to buffer overmethylation. Compound heterozygous and C677T homozygous patients may require 1 to 5 mg of 5-MTHF daily for adequate homocysteine reduction. Always combine with methylcobalamin and monitor homocysteine to confirm therapeutic effect.

Is MTHFR associated with miscarriage?

MTHFR C677T homozygosity and compound heterozygosity are associated with increased risk of recurrent pregnancy loss in some studies, primarily through elevated homocysteine-driven thrombosis in placental vasculature and impaired methylation during the critical early embryonic development period when neural tube closure requires adequate methylfolate. Whether MTHFR testing should be performed in women with recurrent miscarriage is an area of ongoing clinical debate, but most functional medicine providers recommend it as part of a comprehensive preconception evaluation. Women who are pregnant or planning pregnancy and carry MTHFR variants should use methylfolate rather than folic acid.

Clinical Perspective

MTHFR is probably the genetic test I find most clinically actionable in day-to-day practice. When I see a compound heterozygous patient with elevated homocysteine, treatment-resistant depression, histamine intolerance, and fatigue, I know exactly where to start. You switch folic acid to methylfolate, add methylcobalamin and active B6, recheck homocysteine in 8 weeks, and often you see a patient who has struggled for years start to improve. The gene is fixed - but its consequences are absolutely addressable. That is what makes this test worth ordering.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

Find Out If MTHFR Is Affecting Your Health

MTHFR genotyping combined with homocysteine, folate, and B12 assessment gives a complete picture of your methylation cycle function. We interpret your results in clinical context and build a targeted protocol to address impaired methylation at its root.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Genetic testing results should always be interpreted by a qualified healthcare provider with appropriate clinical context. Schedule a consultation to discuss your specific results with Dr. Lamkin.